Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD2461 · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| AZD2461 | DRUG | oral capsules, continuous dosing and intermittent dosing |
Inclusion Criteria: * Patients with confirmed diagnosis of solid tumor malignancy that is not responsive to standard therapies or for which there is no effective therapy. * Eastern Cooperative Group (ECOG) Performance Status score of 0 or 1 * Patients must be 18 years of age * Using adequate contra...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
AZD2461 is an investigational small molecule being studied for the treatment of refractory solid tumors, including cancer tumors. It is in Phase 1 clinical development and is not yet approved by the FDA. The drug is intended for patients with advanced cancers that have not responded to prior therapies.
AZD2461 is being developed by AstraZeneca PLC, a biopharmaceutical company traded on the NASDAQ under the ticker symbol AZN. AstraZeneca is conducting clinical research on this investigational oncology drug for refractory solid tumors.
AZD2461 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by the FDA and is still being evaluated in clinical trials. The drug is being studied for safety and dosing in patients with refractory solid tumors.
AZD2461 has one completed clinical trial, identified as NCT01247168. This was an open-label, dose-escalation study conducted in the United States with 75 participants aged 18 years and older. The trial enrolled patients with refractory solid tumors and cancer tumors.
AZD2461 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development. The completed trial, NCT01247168, was a dose-escalation study, but the drug has not yet received regulatory approval for any indication.